However, Ibrutinib resistance in MCL occurs and it may be attributable to mutations in BCR downstream elements, such as in the NF-κB pathway, BTK or PLCγ2 (Hershkovitz-Rokah et al., 2018). This evidence concerns the gene PLCG2 and mantle cell lymphoma.